[SCHEDULE 13G/A] ArriVent BioPharma, Inc. SEC Filing

Rhea-AI Filing Summary

Novo Holdings A/S reports beneficial ownership of 1,872,142 shares of ArriVent BioPharma, representing 4.99% of the company's common stock. The filing states Novo Holdings has sole voting and sole dispositive power over these shares and does not share voting or dispositive power with any other party.

The filer is a Denmark-based investment holding company that manages assets for the Novo Nordisk Foundation and clarifies the Foundation is not deemed to beneficially own the shares held by Novo Holdings. The filing indicates the position is held without intent to change or influence control of ArriVent.

Positive

• Clear disclosure of exact share count (1,872,142) and percentage (4.99%), improving transparency for the market
• Sole voting and dispositive power is explicitly stated, clarifying who controls voting rights for this block

Negative

• Stake remains below 5%, limiting immediate regulatory or control implications and reducing potential market impact

Insights

Financial Analyst

TL;DR: Novo Holdings holds a 4.99% passive stake with sole voting/dispositive power; not a controlling position.

Novo Holdings' reported ownership of 1,872,142 shares (4.99% of the class) signals a meaningful minority stake but remains below the 5% threshold that typically triggers additional reporting implications. The declaration of sole voting and dispositive power confirms control over voting and disposition of these shares, however the filer explicitly disclaims any intent to influence control. For investors, this is a disclosure of a strategic minority ownership by a life-sciences-focused institutional holder, without immediate governance or control implications.

Corporate Governance Expert

TL;DR: Ownership structure shows clear voting control by Novo Holdings but no apparent attempt to alter company control.

From a governance perspective, sole voting and dispositive power over 4.99% of shares gives Novo Holdings the ability to vote its block cohesively, yet the position is explicitly characterized as not intended to change or influence control. The filing also clarifies the Novo Nordisk Foundation is not treated as a beneficial owner of these shares, narrowing potential attribution questions. This is a routine institutional disclosure rather than an activist or control-seeking move.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ArriVent BioPharma, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

0472N1020

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 0472N1020

1

Names of Reporting Persons

Novo Holdings A/S

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DENMARK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,872,142.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,872,142.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,872,142.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ArriVent BioPharma, Inc.
(b)	Address of issuer's principal executive offices: 18 Campus Boulevard, Suite 100, Newtown Square, PA, 19073.
Item 2.
(a)	Name of person filing: Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies, currently comprised of Novo Nordisk A/S and Novozymes A/S (also known as Novonesis A/S), and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.
(b)	Address or principal business office or, if none, residence: Tuborg Havnevej 19 2900 Hellerup, Denmark
(c)	Citizenship: Denmark
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 0472N1020
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,872,142
(b)	Percent of class: 4.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,872,142
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,872,142
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Novo Holdings A/S

Signature:	Barbara Fiorini
Name/Title:	Barbara Fiorini, General Counsel, Finance & Operations
Date:	08/14/2025

FAQ

How many ArriVent BioPharma (AVBP) shares does Novo Holdings A/S report owning?

Novo Holdings A/S reports beneficial ownership of 1,872,142 shares, representing 4.99% of the common stock.

Does Novo Holdings claim voting or dispositive power over the AVBP shares?

Yes. The filing states Novo Holdings has sole voting power and sole dispositive power over the 1,872,142 shares and reports no shared powers.

Is Novo Nordisk Foundation deemed to beneficially own the ArriVent shares reported?

No. The filing states the Novo Nordisk Foundation is not deemed to have any beneficial ownership of the securities held by Novo Holdings.

Does the filing state Novo Holdings intends to influence control of ArriVent?

The certification in the filing indicates the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

What type of reporting person is Novo Holdings A/S in this filing?

Novo Holdings A/S is classified as a CO (corporation) and is identified as a Denmark-based investment holding company.